Clinical Trials · NCT03211052
A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Centre of Experimental Medicine
- Enrollment
- 16
- Start date
- Feb 2013
- Locations
- 1 site, United Kingdom
- Primary endpoint
- 3 year biochemical progression free survival (PSA)